Literature DB >> 1769286

Cytologic differentiation between proliferative and nonproliferative breast disease in mammographically guided fine-needle aspirates.

S Masood1, E R Frykberg, G L McLellan, S Dee, J B Bullard.   

Abstract

Fine-needle aspiration biopsy (FNAB) is considered a valid diagnostic procedure in management of patients with breast lesions. It is also important to differentiate benign nonproliferative change from proliferative breast changes, since the risk of development of breast carcinoma in patients with atypical hyperplasia is 4-5 times that of general population. Therefore, the recognition of proliferative breast disease with atypia significantly impacts on the patient's subsequent management. To assess the feasibility of a cytologic grading system to further characterize benign breast lesions, cytologic preparation of 87 mammographically guided FNABs were studied. Cellular aspirates were evaluated for the cellular arrangement, the degree of cellular pleomorphism and anisonucleosis, presence of myoepithelial cells and nucleoli and the status of the chromatin pattern. Values ranging from 1 to 4 were assigned to each cytologic criterion, and a score based on the sum of the individual values was calculated for each case. The minimum score attainable was thus 6. In our chosen criteria cytologic diagnosis of nonproliferative disease was entertained when the total score ranged from 6 to 10. Proliferative disease without atypia was diagnosed with a total score ranging from 11 to 14. Atypical hyperplasia was reported when the total score ranged from 15 to 18. A cytologic diagnosis of malignancy was entertained when the total score ranged from 19 to 24. The cytologic diagnosis was then compared to the reported histologic diagnosis from the excisional biopsies and the data were statistically analysed. A high degree of concordance was found between the cytologic findings and the histologic diagnosis. This study suggests that it is possible to apply a cytologic grading system to further subclassify benign breast disease and distinguish these forms from neoplastic lesions.

Entities:  

Mesh:

Year:  1991        PMID: 1769286     DOI: 10.1002/dc.2840070607

Source DB:  PubMed          Journal:  Diagn Cytopathol        ISSN: 1097-0339            Impact factor:   1.582


  6 in total

1.  Evaluation of Masood's and Modified Masood's Scoring Systems in the Cytological Diagnosis of Palpable Breast Lump Aspirates.

Authors:  Smrithi Krishna Cherath; Savithri Moothiringode Chithrabhanu
Journal:  J Clin Diagn Res       Date:  2017-04-01

2.  Tamoxifen downregulates ets oncogene family members ETV4 and ETV5 in benign breast tissue: implications for durable risk reduction.

Authors:  David Euhus; Dawei Bu; Xian-Jin Xie; Venetia Sarode; Raheela Ashfaq; Kelly Hunt; Weiya Xia; Joyce O'Shaughnessy; Michael Grant; Banu Arun; William Dooley; Alexander Miller; David Flockhart; Cheryl Lewis
Journal:  Cancer Prev Res (Phila)       Date:  2011-07-21

Review 3.  Management of in situ and minimally invasive breast carcinoma.

Authors:  E R Frykberg; K I Bland
Journal:  World J Surg       Date:  1994 Jan-Feb       Impact factor: 3.352

Review 4.  Papillary carcinoma of the breast in a male patient with a treated prostatic carcinoma diagnosed by fine-needle aspiration biopsy: a case report and review of the literature.

Authors:  Walid E Khalbuss; Abiy Ambaye; Steve Goodison; Asif Loya; Shahla Masood
Journal:  Diagn Cytopathol       Date:  2006-03       Impact factor: 1.582

5.  Efficacy of Modified Masood Scoring System (MMSS) in Cytological Diagnosis of Breast Lesions.

Authors:  Justina William; Kanwal Masih; Uma Pradhan; Jasneet Kaur; Upinder Singh; Gulshanjit Singh
Journal:  Cureus       Date:  2022-02-16

6.  Expansion of Masood's cytologic index for breast carcinoma and its validity.

Authors:  Ts Rekha; Nm Nandini; Murali Dhar
Journal:  J Cytol       Date:  2013-10       Impact factor: 1.000

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.